Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TATA-box binding protein associated factor 3 (TAF3) is a critical subunit of the TFIID complex responsible for initiating transcription by RNA polymerase II through recognition of gene promoters, both with and without TATA boxes[1][6]. TAF3 interacts directly with the TATA-box binding protein (TBP), histones, and other TAFs, helping to assemble the pre-initiation transcription complex[1][3][6]. It has specialized functions in gene regulation, such as mediating cell differentiation (notably in myogenesis), and acts as a negative regulator of p53—reducing p53 transcriptional activity and protein levels[2][7]. TAF3 is evolutionarily conserved and essential for normal gene expression and cell fate specification; it is not classically considered a therapeutic target such as a receptor or enzyme, but has significant relevance for normal and disease biology due to its central regulatory role in transcription initiation[1][6][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TATA-box binding protein associated factor 3 (TAF3).